Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Receivables (2016 - 2020)

Viridian Therapeutics, Inc.\DE (VRDN) has 7 years of Change in Receivables data on record, last reported at -$48000.0 in Q4 2020.

  • For Q4 2020, Change in Receivables rose 94.49% year-over-year to -$48000.0; the TTM value through Dec 2020 reached -$99000.0, down 217.86%, while the annual FY2020 figure was -$99000.0, 217.86% down from the prior year.
  • Change in Receivables reached -$48000.0 in Q4 2020 per VRDN's latest filing, up from -$191000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $3.4 million in Q1 2018 and bottomed at -$3.6 million in Q2 2018.
  • Average Change in Receivables over 5 years is $450.0, with a median of $53500.0 recorded in 2016.
  • Peak YoY movement for Change in Receivables: plummeted 2044.12% in 2016, then soared 7363.64% in 2017.
  • A 5-year view of Change in Receivables shows it stood at $11000.0 in 2016, then skyrocketed by 7363.64% to $821000.0 in 2017, then tumbled by 265.41% to -$1.4 million in 2018, then skyrocketed by 35.86% to -$871000.0 in 2019, then skyrocketed by 94.49% to -$48000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$48000.0 in Q4 2020, -$191000.0 in Q3 2020, and $244000.0 in Q2 2020.